ArticleFrontiers in pharmacology2024

Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China.

Lu Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.